Furthermore, a promising OS was achieved after membrane HSP70 (mHSP70) positive stage IIIb non-small cell lung carcinoma (NSCLC) patients were treated with combination therapy of radiochemotherapy (RCT), HSP70 peptide, Interleukin-2 (IL-2) activated NK cells, and PD-1 inhibition [62]. The gene discussed is HSPA1A; the disease is non-small cell lung carcinoma.